الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 64 |  |  |
| | | from | 64 | | |
Abstract
Chondroblastoma is a rare, benign bone tumor that typically occurs in the epiphysis (ends) of long bones, most commonly in young individuals. Treatment options for chondroblastoma depend on factors such as the tumor size, location, and the patient’s overall health. Here’s a summary of the typical treatment approaches for chondroblastoma:
1. Objective: The study aimed to assess the clinical and radiological outcomes of extended curettage with or without bone grafting in patients diagnosed with chondroblastoma.
2. Patient characteristics:
o Study Design: Retrospective analysis of 20 patients treated at El-Hadara University Hospital between January 1, 2018, and December 31, 2021.
o Inclusion Criteria: Patients with isolated chondroblastoma of the upper or lower extremity.
o Exclusion Criteria: Patients with other benign bone tumors, associated fractures, or a history of previous fractures or deformities ipsilaterally.
o Demographics: Mean age of 16.0 years, with a male predominance (70.0%). Majority of cases involved the right side (60.0%).
3. Clinical Data:
o Affected Sites: Common sites included distal femur and proximal tibia.
o Follow-up Period: Ranged from 20.0 to 47.0 months, mean of 36.10 months.
4. Surgical Treatment:
o All cases underwent extended curettage without bone grafting.
5. Assessment:
o Functional Outcome: Evaluated using the Musculoskeletal Tumor Society (MSTS) scoring system. Scores ranged from 25.0 to 30.0, with a mean of 27.50 ± 1.32, indicating favorable functional outcomes.
o Radiological Outcome: Recurrence occurred in 10.0% of cases, while 90.0% did not experience recurrence, indicating positive tumor control outcomes.
6. Statistical Analysis:
o Conducted using IBM SPSS softwar